ProPhase Q3 net loss $6.8M, revenue down 36%; working capital deficit $47.5M

ProPhase Labs, Inc.

2025-Q3 EPS reported -$0.19 revenue$3,561,000

Q3 net loss from continuing ops $6.8M ($0.16/sh) vs $5.0M ($0.26/sh) prior year; revenue $0.9M down from $1.4M
Cash $405K; working capital deficit $47.5M at Sep 30 vs $1.5M at Dec 31, 2024
Crown Medical appointed Special Counsel to recover $50M+ net A/R; first settlement completed
BE-Smart esophageal cancer test validated by Mayo Clinic; commercialization rollout underway
Nebula Genomics pro-forma profitable; strategic M&A discussions ongoing

item 2.02item 7.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.